Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer


Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, who spotlighted agents that are currently used for the treatment of RET fusion–positive thyroid cancer. Although only a subset of patients with papillary thyroid cancer have disease that is driven by RET fusions, over half of all patients with medullary disease have RET mutations. Due to this, RET is believed to play an important role in the treatment of thyroid cancer


One of the things that we knew about for a long time is that a subset of thyroid cancers are driven by RET fusion genes [in papillary disease]. For medullary [disease], on other hand, probably about 55% or 60% are driven by RET mutations, either hereditary or somatic. We know RET plays a very important role in the treatment of thyroid cancers. A lot of the treatments that started out for medullary thyroid cancer were really based on the fact that certain drugs like cabozantinib [Cabometyx] and vandetanib [Caprelsa] targeted RET. Because of that, although these drugs hit many different targets, pretty good activity was seen and both vandetanib and cabozantinib got FDA approvals. [However], other drugs like sunitinib [Sutent], pazopanib [Votrient], and lenvatinib [Lenvima] were also shown to have reasonable activity, although they never went through randomized phase 3 studies.


Sherman EJ, Wirth LJ, Shah MH, et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a clinical trial update. J Clin Oncol. 2021;39(suppl 15):6073. doi:10.1200/JCO.2021.39.15_suppl.6073

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content